07:00 , Apr 24, 2006 |  BC Week In Review  |  Company News

American Bioscience, American Pharmaceutical Partners deal

American BioScience completed its previously announced merger with its APPX majority-owned subsidiary in a stock deal to form Abraxis BioScience Inc. (see BioCentury, Dec. 5, 2005). The newco trades on NASDAQ under the symbol ABBI....
08:00 , Mar 27, 2006 |  BC Week In Review  |  Company News

American Pharmaceutical Partners management update

American Pharmaceutical Partners Inc. (APPX), Schaumburg, Ill.   Business: Cancer, Generics   Hired: Joseph Hogan as VP of U.S. sales and marketing at APPX's Abraxis Oncology unit, formerly head of global oncology marketing at Schering...
08:00 , Mar 20, 2006 |  BC Week In Review  |  Company News

Novacea management update

Novacea Inc. , South San Francisco, Calif.   Business: Cancer, Hematology   Hired: Amar Singh as CCO, formerly VP sales and marketing at American Pharmaceutical Partners Inc.'s Abraxis Oncology unit  ...
08:00 , Dec 5, 2005 |  BC Week In Review  |  Company News

American Bioscience, American Pharmaceutical Partners deal

American BioScience will merge with its APPX majority-owned subsidiary in a stock deal. American BioScience shareholders, who currently own 64.4% of APPX, will own 83.5% of the combined entity. The deal is expected to close...
03:02 , Nov 17, 2005 |  BC Extra  |  Company News

American BioScience, Taiho Abraxane deal

American BioScience (Santa Monica, Calif.) granted Taiho (Tokyo, Japan) exclusive Japanese development and commercialization rights to Abraxane paclitaxel to treat breast, lung, gastric and other solid tumors. American BioScience could receive up to $50 million...
08:00 , Nov 7, 2005 |  BC Week In Review  |  Clinical News

Abraxane paclitaxel: Phase I data

Data from an open-label, U.S. Phase I trial in 39 patients showed that the MTDs of ABI-007 were 100 and 150 mg/m 2 for lightly and heavily pretreated patients, respectively. Patients received an average of...
07:00 , Jun 20, 2005 |  BC Week In Review  |  Clinical News

Abraxane paclitaxel regulatory update

The partners submitted a marketing application to Health Canada for Abraxane to treat metastatic breast cancer. The solvent-free nanoparticle albumin-bound formulation of paclitaxel was approved in the U.S. for the same indication in January. (see...
07:00 , May 9, 2005 |  BC Week In Review  |  Clinical News

Abraxane paclitaxel: Completed Phase II enrollment

The partners completed enrollment of 30 patients in an open-label, U.S. Phase II trial. The patients are receiving Adriamycin plus Cytoxan every 2 weeks for 4 cycles followed by 260 mg/m 2 Abraxane in a...
07:00 , Apr 11, 2005 |  BC Week In Review  |  Clinical News

Abraxane paclitaxel: Phase II started

APPX started an open-label Phase II study in 70 patients with locally advanced or metastatic breast cancer. All patients will receive weekly 125 mg IV Abraxane paclitaxel for weeks 1-3 in each 4-week treatment cycle....
07:00 , Apr 4, 2005 |  BioCentury  |  Finance

1Q Approvals & Setbacks

1Q Approvals & Setbacks Selected first quarter product approvals. Company Approval American Pharmaceutical Partners (APPX) FDA approves Abraxane paclitaxel formulation to treat metastatic breast cancer Amylin (AMLN) FDA approves Symlin pramlintide to treat Type I...